Ricardo Viais, PhD

AccelBio is a biotech R&D non-profit based in Portugal created in 2022 and dedicated to accelerating the translation, commercialization, and global dissemination of cutting-edge biomedical discoveries and innovations originating from premier research and development centers in Portugal, and beyond. AccelBio’s mission is clear: to bridge the gap between academic research and the pharmaceutical industry, expediting the journey from scientific discovery to patient treatment. The organization is committed to transforming the "Valley of Death"—the often perilous and failure-prone phase of drug discovery—into a window of opportunity. By establishing state-of-the-art drug discovery tools and technologies, AccelBio aims to develop early drug discovery projects that meet industry standards. To accomplish its mission, Accelbio has with different associates from pharma/ biotech to academic centers, an investment organization and a biotech park. Associates include big pharma as Roche, biotech as Valvian, TargeTx, Vertical Sentinel, BSIM Therapeutics and Basinnov. Biovance Capital on the side of investment fund and Biocant, the biotech park. Universidade de Coimbra, Gulbenkian Instituto for Molecular Medicine and Instituto Superior Técnico are our academic associates. We are a R&D organization using a novel rational approach to support drug development from academia combining different capabilities: 1- Human Organoids (based on iPSC); 2- Multiomics and computational biology in human samples; 3- Drug design and computational chemistry; 4- High Throughput screening; 5- Preclinical in vivo studies (ADMET). These capabilities are being used to develop our own assets (drugs and/ or biomarkers) and platforms, and we are open to partnerships on our fields of action.  Furthermore we also have in our team dedicated Translational Researchers that give tailored support to individual projects building effective roadmaps from bench to market and ensuring high quality standards. Our therapeutic areas coverage includes: - CNS - Immuno- Oncology and Inflammation - Anti-infectives - Cardiovascular - Nephrology We are agnostic when it comes to the type of molecules in our pipeline (from small molecules to large molecules).   Our business model includes licensing agreements, seed- funding for our assets, R&D partnerships and collaborations on our core activities, not excluding providing services.